CSBio CSBio

X
[{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","amount":"$17.3 million","upfrontCash":"Undisclosed","newsHeadline":"Genespire Secures \u20ac16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Genespire"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The funds will be used to advance Genespire’s leading-edge platform technologies towards the development of novel gene therapies in primary immunodeficiencies and metabolic genetic diseases.

            Lead Product(s): Gene Therapy

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Sofinnova Partners

            Deal Size: $17.3 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing April 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY